Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | NPY1R | P25929 | 1/20 | 0.65 |
| ▸ | NPY2R | P49146 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324721 | 0.90 | POLB (0.79) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL30049353 | 0.90 | POLB (0.79) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL27933692 | 0.87 | POLB (1.00) | POLBNPSR1MAPTHTTRAB9A | |
| SCHEMBL13621801 | 0.87 | LMNA (0.68) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL4363056 | 0.87 | POLB (0.67) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL5426578 | 0.86 | NPSR1 (0.65) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL24273311 | 0.85 | NR4A2 (0.67) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL6086011 | 0.84 | TUBB4A (0.64) | POLBNPSR1MAPTHTTKDM4E | |
| SCHEMBL6527769 | 0.84 | HTT (0.76) | POLBNPSR1MAPTHTTRAB9A | |
| SCHEMBL6192840 | 0.82 | POLB (0.53) | POLBNPSR1MAPTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103508930-B | Two (aminodithioformic acid)-1,3-propylene diester compounds and synthetic method, pharmaceutical composition and purposes | PEKING UNIVERSITY (CN) | 2016-01-27 | — | — | CN | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1956910-B1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-1956910-B1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | POLB 3531/4885NPSR1 2378/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.